SCHEMBL5022702

SCHEMBL5022702

Nc1ncccc1N1CCNCC1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.61
HTR2C P28335 1/20 0.61
SLC6A4 P31645 1/20 0.61
HTR7 P34969 1/20 0.55
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
PLD1 Q13393 1/20 0.51
EPHX2 P34913 1/20 0.51
ADRB1 P08588 2/20 0.50
HTR1A P08908 1/20 0.50
SLC6A2 P23975 1/20 0.50
PRKCA P17252 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCD Q05655 1/20 0.49
ADRB2 P07550 1/20 0.49
NCF1 P14598 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29359704 1.00 HTR2A (0.61) HTR2AHTR2CSLC6A4HTR7KDM4E
SCHEMBL30443783 0.83 KEAP1 (0.52) HTR2AHTR2CSLC6A4KDM4EALDH1A1
SCHEMBL31563732 0.83 KEAP1 (0.47) HTR2AHTR2CSLC6A4KDM4EALDH1A1
SCHEMBL29118465 0.83 KEAP1 (0.52) HTR2AHTR2CSLC6A4KDM4EALDH1A1
SCHEMBL5067333 0.81 KEAP1 (0.55) KDM4EALDH1A1NCF1
SCHEMBL10495676 0.80 HTR2C (0.68) HTR2AHTR2CSLC6A4HTR7KDM4E
SCHEMBL17506189 0.80 NOS3 (0.39) HTR2AHTR2CSLC6A4HTR7
SCHEMBL18284881 0.79 ADRA2C (0.58) KDM4EPRKCQNCF1
SCHEMBL823332 0.79 ALDH1A1 (0.48) KDM4EALDH1A1NCF1
SCHEMBL21384494 0.79 HTR2A (0.61) HTR2AHTR2CSLC6A4HTR7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023125908-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-07-06 WO disclosed
EP-3883928-A1 GLP-1R AGONISTS AND USES THEREOF Qilu Regor Therapeutics Inc. (CN) 2021-09-29 EP disclosed
CN-108586356-A Rui Boxini new intermediates and its synthetic method for preparing Rui Boxini 杭州科巢生物科技有限公司 2018-09-28 CN disclosed
EP-3302465-A1 TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES Vertex Pharmaceuticals Incorporated (US) 2018-04-11 EP disclosed
WO-2016197009-A1 TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-08 WO disclosed
EP-1893607-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-03-05 EP disclosed
WO-2006135604-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-12-21 WO disclosed
EP-1373247-A2 SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF TANABE SEIYAKU CO., LTD. (JP) 2004-01-02 EP disclosed
WO-2002079189-A2 SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES TANABE SEIYAKU CO., LTD. (JP) 2002-10-10 WO disclosed